What Researchers Did
Scientists studied how hyperbaric oxygen therapy (HBOT) changes gut bacteria and immune activity in people with ulcerative colitis, using samples from a clinical trial and follow-up experiments in mice.
What They Found
This laboratory and clinical-sample study found that patients who responded to HBOT showed distinct biological changes compared to those who did not, based on analysis of biopsy, tissue, and stool samples. HBOT response was linked to lower levels of certain neutrophil (immune cell) markers, including reduced neutrophil STAT3 activity, confirmed through multiple lab techniques. HBOT also reduced the diversity of gut bacteria, increased the Firmicutes bacterial group and a substance called lithocholic acid, and reduced bacteria that stick to the gut lining while increasing a protective mucus protein (MUC2). Differences in one specific bacterial strain, Akkermansia muciniphila, were associated with whether patients responded to HBOT or not.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The study combines a small set of human clinical trial samples with mouse experiments and reports associations rather than proof that these biological changes cause improved or worsened colitis outcomes.